ABCL AbCellera Biologics Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:50
Aug 31
Aug 31
Short ABCL, add near $12
Short AbCellera and press the position if it rebounds to around $12, using that level as the trigger for adding.
HIGH
13:53
Aug 28
Aug 28
Short ABCL targeting single digits
Short ABCL with a new position targeting single digits; detailed commentary is deferred to the next weekly, and no catalyst is specified beyond the price objective.
MED
18:00
Aug 26
Aug 26
ABCL weekly intact despite sell signals
Notes ABCL is at a technical setup after a ~120% run; two sell signals have appeared but the weekly timeframe remains intact.
MED
15:24
Aug 26
Aug 26
The author expresses hypothetical interest in biotech via ABCL after preliminary research.
The author expresses hypothetical interest in biotech via ABCL after preliminary research, but frames it as conditional rather than a current position or explicit buy call.
LOW
14:54
Aug 26
Aug 26
The author notes ABCL is a biotech name many like without typical biotech concerns.
The author notes ABCL is a biotech name many like without typical biotech concerns, but expresses no personal position or directional call.
LOW
13:28
Aug 26
Aug 26
The author admits to not having researched ABCL and expresses fear of biotech.
The author admits to not having researched ABCL and expresses fear of biotech, showing no directional view.
LOW
22:40
Aug 25
Aug 25
ABCL seen dipping to $8-9 then rallying
Buy ABCL for an expected pullback to $8-9 before a larger rally; it is viewed as a rare quality name.
LOW
14:13
Aug 25
Aug 25
Author agrees with a parent post about healthcare leadership but only lists tickers without.
Author agrees with a parent post about healthcare leadership but only lists tickers without stating a position or forward call, so they are watch items.
LOW
14:40
Aug 23
Aug 23
"Hold ABCL long despite near-term resistance"
"Hold ABCL long as an existing position; the author previously cited technicals, fundamentals, and a broader thesis as a clear buying opportunity, while this reply flags near-term resistance."
MED
14:46
Aug 21
Aug 21
Author clarifies he publicly closed a prior trade to buy more ABCL and IOVA.
Author clarifies he publicly closed a prior trade to buy more ABCL and IOVA, but does not state current positions or forward direction.
LOW
15:47
Aug 20
Aug 20
The author reassures a seller that they can buy back the stock later.
The author reassures a seller that they can buy back the stock later, offering comfort rather than a directional trade call.
03:38
Aug 20
Aug 20
Author acknowledges hearing of ABCL in reply but expresses no directional view.
Author acknowledges hearing of ABCL in reply but expresses no directional view, merely confirming awareness of the name.
LOW
23:56
Aug 19
Aug 19
Author takes profits on ABCL position.
Author discloses taking profits on ABCL position to rotate capital into a higher conviction trade.
MED
18:25
Aug 19
Aug 19
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward.
Author acknowledges a biotech list with eye emojis but gives no explicit position or forward call, so all tickers are indexed as watch.
LOW
15:41
Aug 18
Aug 18
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not.
Author names ABCL as his favorite pick while viewing PRME and RXRX as promising but not explicitly held, making ABCL a clear long and the others watch.
00:01
Aug 18
Aug 18
Long ABCL on antibody AI drug-discovery platform
Long ABCL for its AI drug-discovery platform thesis: it maps the immune system, screens millions of cells, and aims to become the operating system pharma uses to find antibody treatments.
MED
11:28
Aug 15
Aug 15
The author lists a large basket of tickers without any explicit position language.
The author lists a large basket of tickers without any explicit position language or directional thesis, so all are indexed as watch.
LOW
21:25
Aug 14
Aug 14
Insider buys make ABCL bullish.
Buy ABCL; the author views the disclosed insider purchase of 46,387 shares around $10.37 by Michael Hayden as a bullish signal, favoring insider buying over the many reasons to sell.
MED
15:21
Aug 14
Aug 14
Author takes profit on overvalued ABCL.
Author took profits on their ABCL position after a 3x gain, citing current overvaluation.
HIGH
14:51
Aug 14
Aug 14
Profits rotated out of ABCL into IOVA
Author took profits on ABCL and rotated proceeds into IOVA; partial exit from ABCL position disclosed.
MED
20:04
Aug 13
Aug 13
Author complains their short book is underperforming while longs dominate.
Author complains their short book is underperforming while longs dominate, listing prior short candidates as context rather than fresh trade calls.
05:02
Aug 13
Aug 13
ABCL long on disciplined capital raise
Buy ABCL; management demonstrated capital discipline by not upsizing an oversubscribed $200M raise, and proceeds are earmarked for growth and fulfillment, signaling quality capital allocation.
MED
17:13
Aug 12
Aug 12
Questions competitive advantage of antibody discovery platform
Questions the competitive advantage of the company's antibody discovery platform compared to hundreds of peers, noting a lack of explanation from retail bulls.
LOW
15:56
Aug 12
Aug 12
ABCL cult premium collapses on commoditized platform
Short ABCL as a cult-driven overvaluation built on a commoditized antibody discovery platform with no durable differentiation; even a successful FDA approval will yield disappointing launch revenues, and pipeline failures will eventually expose the stock's terminal weakness.
MED
12:55
Aug 12
Aug 12
Author dismisses ABCL's valuation as memey and notes weak Veozah sales.
Author dismisses ABCL's valuation as memey and notes weak Veozah sales, but offers no explicit short position or downside target.
10:47
Aug 12
Aug 12
ABCL called overvalued meme stock
Author labels AbCellera Biologics overvalued and a meme stock within a short-selling list; valuation criticism only, no specific deterioration mechanism stated.
LOW
15:36
Aug 11
Aug 11
Short-term trade position, early entry noted
Author lists ABCL as a current short-term trade position with no specific catalyst articulated beyond early entry timing.
LOW
15:09
Aug 11
Aug 11
Author clarifies they do not own Abcellera despite the shoutout.
Author clarifies they do not own Abcellera despite the shoutout, so no position or directional view is expressed.
LOW
23:52
Aug 10
Aug 10
The author discusses using AI and social tracking to predict biotech trial results.
The author discusses using AI and social tracking to predict biotech trial results, referencing ABCL as an example of their research method rather than stating a current position or explicit trade call.
LOW
19:40
Aug 10
Aug 10
AbCellera shares surged up to 41 percent after reporting positive mid-stage trial results.
AbCellera shares surged up to 41 percent after reporting positive mid-stage trial results for a hot flash treatment candidate.
About ABCL Analyst Coverage
Buzzberg tracks ABCL (AbCellera Biologics Inc.) across 14 sources. 28 bullish vs 2 bearish calls from 16 analysts. Sentiment: predominantly bullish (31%). 84 total trade ideas tracked. Past 7 days: 2 bearish. Latest voices: seedy19tron, wliang, itschrisray.